Smith & Nephew plc (SN) Given Buy Rating at Goldman Sachs Group Inc.
Smith & Nephew plc (LON:SN)‘s stock had its “buy” rating restated by equities research analysts at Goldman Sachs Group Inc. in a report released on Tuesday.
Several other research analysts have also recently issued reports on the company. Credit Suisse Group AG upped their price objective on Smith & Nephew plc from GBX 1,165 ($15.52) to GBX 1,325 ($17.65) and gave the stock a “neutral” rating in a research report on Friday, July 8th. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 1,242 ($16.54) price objective on shares of Smith & Nephew plc in a research report on Friday, June 24th. Jefferies Group upped their price objective on Smith & Nephew plc from GBX 1,375 ($18.31) to GBX 1,420 ($18.91) and gave the stock a “buy” rating in a research report on Thursday, June 30th. BNP Paribas reaffirmed an “outperform” rating and set a GBX 1,335 ($17.78) price objective on shares of Smith & Nephew plc in a research report on Monday, June 27th. Finally, Barclays PLC cut Smith & Nephew plc to an “equal weight” rating and upped their price objective for the stock from GBX 1,230 ($16.38) to GBX 1,240 ($16.52) in a research report on Wednesday, August 10th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of GBX 1,294.92 ($17.25).
Shares of Smith & Nephew plc (LON:SN) traded down 0.16% on Tuesday, reaching GBX 1230.00. The company had a trading volume of 6,185,534 shares. Smith & Nephew plc has a 52 week low of GBX 1,040.36 and a 52 week high of GBX 1,324.00. The company’s 50-day moving average price is GBX 1,244.08 and its 200 day moving average price is GBX 1,197.20. The firm’s market capitalization is GBX 11.00 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/smith-nephew-plc-sn-given-buy-rating-at-goldman-sachs-group-inc.html
In other news, insider Bottomley ,Virginia acquired 238 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was purchased at an average cost of GBX 1,290 ($17.18) per share, with a total value of £3,070.20 ($4,089.24).
Smith & Nephew plc Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.
Receive News & Ratings for Smith & Nephew plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Smith & Nephew plc and related companies with MarketBeat.com’s FREE daily email newsletter.